Welcome, Guest

Jay Tiesman, PhD

Jay Tiesman, PhD

Procter & Gamble Company's Jay Tiesman, PhD, discusses the role of genomics in the cosmetics industry.

Jay Tiesman, Principal Scientist and Genomics Group Leader at Procter & Gamble stated, "Our labs can measure not only what's going on at the top of the skin but also how it responds from the inside. We're gauging its responses to exterior damage as well as nutrition: What nutrition triggers a response on the skin's surface? There are still a lot of magic potions out there, but we actually have a much better understanding of beauty products with much more soon to come." (Fast Company, January, 2009).

Comparing young and old skin, we were able to identify a number of pathways that are either down-regulated or up-regulated as skin ages.

We have incorporated genomics technologies into the research programs behind nearly all of our products, so when you think of a P&G product, there are likely a number of experiments utilizing GeneChip® technology behind them. Our real interest has been to understand how the consumer responds to the environment and how our products may help to improve this interaction. Gene expression profiling is a very powerful way of measuring this at a biological level. We use GeneChip technology for skin and hair studies, oral care, respiratory care, gastrointestinal care, and many others. We also have a very active safety program where we use genomics in our continued attempts to replace animal studies with in vitro screening assays.

Read the full article. Download the pdf version to enjoy the article in it's entirety and also keep it for future reference. Avaliable in PDF (992 KB)

More Scientist Spotlights

  • Mady Hornig, MD Mady Hornig, MA, MD, Director of Translational Medicine at Columbia University, discusses the use multiplexed immunoassays for studying chronic fatigue syndrome, known as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
  • Jizeng Jia, PhD Jizeng Jia, PhD, from the Institute of Crop Sciences, Chinese Academy of Agriculture Science, Beijing, discusses the limitations of current technologies and how they were overcome to develop the highest density wheat array commercially available.
  • Gordon Mills, MD Gordon Mills, MD, PhD, of the University of Texas MD Anderson Cancer Center and "Dream Team" co-leader in Stand Up To Cancer®, discusses the importance of genomic profiling in the discovery of novel predictive markers to improve the effectiveness of cancer treatment.
  • Mark I. McCarthy, MD Professor Mark McCarthy, from the University of Oxford, UK, outlines how the intersection of biobank capabilities, new study designs, and technological advances will improve our understanding of complex trait genetics.
  • Bruno Stuhlmüller, PhD Bruno Stuhlmüller, PhD, head of the scientific laboratory and team leader at the Institute of the Rheumatology and Clinical Immunology department at the Charité Free University and Humboldt University, Berlin, discusses working with whole blood samples to identify mRNA and miRNA biomarkers for predictive rheumatoid arthritis treatments.
  • Peter Ambros, PhD Peter Ambros, PhD, Associate Professor at the Children's Cancer Research Institute (CCRI) in Vienna, Austria discusses the way in which arrays are helping to unravel the complexities of the cancer genome and guiding patient-tailored treatment strategies.
  • Austin Tanney, PhD Austin Tanney, PhD, Scientific Liaison Manager for Almac Diagnostics, UK, discusses the opportunities and challenges of working with FFPE tissue, and his visions for technologies driving towards personalized medicine.
  • Jay Tiesman, PhD Procter & Gamble Company's Jay Tiesman, PhD, discusses the role of genomics in the cosmetics industry.
  • Joshua Schiffman, MD The University of Utah's Joshua Schiffman, MD, discusses the use of molecular inversion probe (MIP) technology for studying copy number alterations in pediatric cancers.
  • Lisa Baumbach, MD The University of Miami's Lisa Baumbach and Maastricht University's Torik Ayoubi discuss how ethnicity-specific genetic changes govern aggressive breast cancer risks.
  • Chris Smith, PhD Chris Smith of Cambridge University, Tyson Clark of Affymetrix and Melissa Cline of UCSC discuss EURASNET's approach for comparing commercial microarrays.
  • Robert Norgren, PhD Rob Norgren of The University of Nebraska Medical Center and Katja Nowick of Lawrence Livermore National Laboratory discuss the development of the Rhesus Macaque Genome Array.
  • Yong-Jie Lu, PhD Yong-Jie Lu of Queen Mary, University of London and Colleen Elso of the Walter and Eliza Hall Institute discuss a method for rapidly identifying chromosome rearrangements.

Scientist Spotlights

Publications

Archived Webinars

Warning! The earliest signals for cancer – miRNA regulation

Jay Tiesman, PhD | Researchers | Community